Bridge Biotherapeutics, a Korean biotech firm, announced positive feedback from the third Independent Data Monitoring Committee (IDMC) meeting to continue the phase 2 clinical trial of BBT-877, a drug candidate for the treatment of idiopathic pulmonary fibrosis (IPF).IPF is a severe and chronic lung
The Ministry of Food and Drug Safety has granted approval to two more digital therapeutic (DTx) devices, developed by Nunaps and Share&Service. These devices, which are the third and fourth authorized DTx in the country, utilize software to assist in cognitive improvement and respiratory rehabilitat
3Bigs, a Korean company specializing in bio big data-based health management solutions, said it entered a distribution partnership with Neo-Science, a bio-health enterprise located in Abu Dhabi, the UAE.Under the accord, Neo-Science will manage the sales of several key 3Bigs products, including the
HLB said it opened a new office in the Cambridge Innovation Center (CIC) in Boston, U.S. to bolster the collaboration and communication between HLB and its U.S. subsidiaries, such as Immunomic Therapeutics, while also supporting its group companies' entry into international markets.HLB's new office
Handok and Swedish Orphan Biovitrum (Sobi) said they have officially inaugurated their Korean joint venture, Handok-Sobi.Sobi is a global biopharmaceutical company specializing in rare diseases, providing innovative treatments in hematology, immunology, and specialized therapies. With 1,800 employee
GC Cell said its U.S. affiliate Artiva Biotherapeutics has begun administering the first dose to a participant in a phase 1 clinical trial. This trial investigates the combination of AlloNK (AB-101) and rituximab as a potential treatment for lupus nephritis.Lupus nephritis is a complication of syste
Celltrion announced its decision to further buy back and retire its own shares as part of its ongoing efforts to stabilize its stock price and enhance shareholder value.The company stated that it would purchase approximately 436,047 shares for a total acquisition cost of about 75 billion won ($54.1
BNC Korea said it secured exclusive distribution rights in five Asian countries for Danish biotech firm Kariya's KP405 and KP404, both Alzheimer's and Parkinson's drug candidates that can cross the blood-brain barrier.The agreement, which encompasses Korea, Singapore, Thailand, Indonesia, and Malays
A research team at Korea University Guro Hospital (KUGH) and Harvard Medical School has developed the "world’s first" dual fluorescence imaging technique for precision lung cancer surgery.Recent developments in lung cancer surgery aim to completely remove cancer tissues while preserving as much heal
DongKoo Bio & Pharma, a Korean company known for its dermatological products, has announced a strategic investment of 10 billion won ($7.2 million) into Qurient, a local biotech, becoming its largest shareholder.Through this latest investment, DongKoo will acquire approximately 2.56 million new shar
Handok said it finalized an exclusive distribution and supply agreement with Nxera Pharma Korea, the offshoot of a Japan-based pharmaceutical company Nxera, for Pivlaz, a drug designed to prevent cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysm
Unlike many other global pharmaceutical giants choosing to divest and spin-off units, Bristol Myers Squibb (BMS) is aggressively expanding its pipeline through open innovation and strategic acquisitions.As a leading biopharma company, BMS is enhancing its presence across multiple therapeutic areas,
OliX Pharmaceuticals, a Korean biotech firm specializing in RNA interference technologies, recently announced the promising results of its hair loss treatment, OLX104C, at the 13th World Congress for Hair Research (WCHR 2024) held in Texas, the U.S. from April 6-9.The WCHR, hosted by the Internation
A technology that sequentially releases antibiotics and growth agents to enhance bone regeneration has been developed by a collaborative research team from Yonsei University.Patients suffering from chronic inflammatory bone diseases such as periodontal disease or osteoporosis experience slow bone re
Samsung Bioepis has achieved a significant milestone by obtaining the first domestic approval for a biosimilar referencing Janssen's Stelara, Epyztek (ingredient: ustekinumab), on Thursday.Stelara, originally developed by Janssen, is utilized in the treatment of plaque psoriasis, psoriatic arthritis
Celltrion said Yuflyma (ingredient: adalimumab), a biosimilar referencing Humira, has been included in the formulary of one of the top three pharmacy benefit managers (PBMs) in the U.S. The three largest PBMs in the U.S., which include CVS Health, Express Scripts, and Optum, collectively manage abou
NKMAX, a local biotech firm specializing in NK cell therapy, announced plans to file an objection to its potential delisting from the Korea Exchange (KRX).The company, which has been listed on the Kosdaq since August 2018, is facing delisting due to significant operational challenges.On March 5, NKM
A research team at the Seoul National University Bundang Hospital (SNUBH) developed an artificial intelligence (AI) model that significantly improves the prediction of mortality rates in patients undergoing extracorporeal membrane oxygenation (ECMO), the hospital said.ECMO, a critical life-support s
Kakao Healthcare said it was invited to speak at the Google Cloud Next 2024 Conference.Google Cloud Next Conference, which is currently being held from Tuesday to Thursday (local time) in Las Vegas, U.S., is an annual tech conference hosted by Google Cloud.During the conference, Kakao Healthcare par
Recent advancements in HIV treatment and prevention, including the roll-out of pre-exposure prophylaxis (PrEP) and the bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) treatment regimen, have highlighted the critical need for ethnic-centered approaches in healthcare.Therefore, understanding